Methods
A total of 48 consecutive patients with non-ischemic cardiomyopathies
who underwent CRT upgrades were retrospectively reviewed and divided
into three groups: group 1 included CS patients taking corticosteroids
before the CRT upgrade (n = 7), group 2, CS patients not taking
corticosteroids before the CRT upgrade (n = 10), and group 3, non-CS
patients (n = 31). The echocardiographic response, heart failure
hospitalizations, and cardiovascular deaths were evaluated.